natgillin/translations-raw huggingface dataset:
Children and adolescents - Levetiracetam Accord is not indicated in children and adolescents below 16 years on its own 
• Zdravilo Levetiracetam Accord pri otrocih in mladostnikih, mlajših od 16 let, ni indicirano za samostojno zdravljenje (monoterapija).
Film-coated tablet The tablet can be divided into equal halves 
Po peroralnem dajanju se lahko okusi grenak okus levetiracetama.Dnevni odmerek se daje razdeljen v dva enaka odmerka.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Box of 10, 20, 30, 50, 60, 100, 200 tablets 
PODATKI NA ZUNANJI OVOJNINI Škatla z 10, 20, 30, 50, 60, 100 in 200 tabletami
10 to 30 mg /kg (0.10 to 0.30 ml/kg) twice daily 
10 do 30 mg/kg (0,10 do 0,30 ml/kg) dvakrat na dan blaga ledvična okvara
Your doctor will prescribe the most appropriate pharmaceutical form of levetiracetam according to the age, weight and dose. 
Zdravnik vam bo glede na starost, telesno maso in odmerek predpisal najprimernejšo farmacevtsko obliko zdravila Levetiracetam Accord.
(3) A 15 mg /kg (0.15 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam. 
(3) Prvi dan zdravljenja z levetiracetamom je priporočljiv začetni odmerek 15 mg/kg (0,15 ml/kg).
Therefore a 50 % reduction of the daily maintenance dose is recommended when the creatinine clearance is < 60 ml/min/1.73m2. 
Če je očistek kreatinina < 60 ml/min/1,73 m2, je priporočljivo zmanjšati dnevni vzdrževalni odmerek za 50 %.
Levetiracetam Accord film-coated tablets 250 mg, 500 mg, 750 mg and 1000 mg are packed in PVC-Alu blister pack. 
Levetiracetam Accord filmsko obložene tablete 250 mg, 500 mg, 750 mg in 1.000 mg so pakirane v
INFORMATION IN BRAILLE Levetiracetam Accord 1000 mg 
Levetiracetam Accord 1.000 mg
750 mg: polyvinyl alcohol, titanium dioxide (E171), macrogol, talc, iron oxide red (E172), sunset yellow FCF(E110) 
polivinilalkohol, titanov dioksid (E171), makrogol, smukec, rumeni železov oksid (E172) 750 mg: polivinilalkohol, titanov dioksid (E171), makrogol, smukec, rdeč železov oksid (E172), oranžna FCF
Levetiracetam Accord 750 mg film-coated tablets Each film-coated tablet contains 750 mg levetiracetam 
Levetiracetam Accord 750 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 750 mg levetiracetama.
Drug reaction with eosinophilia and systemic symptoms (DRESS), Hypersensitivity (including angioedema and anaphylaxis) 
preobčutljivost (vključno z angioedemom in anafilakso)
(2) A 10.5 mg /kg (0.105 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam. 
(2) Prvi dan zdravljenja z levetiracetamom je priporočljiv začetni odmerek 10,5 mg/kg (0,105 ml/kg).
Levetiracetam Accord 500 mg film-coated tablets Each film-coated tablet contains 500 mg levetiracetam 
Levetiracetam Accord 500 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 500 mg levetiracetama.
Levetiracetam Accord 750 mg film-coated tablets Pink coloured, oval, biconvex, debossed ‘L 66' and break line on one side and plain on the other side. 
Levetiracetam Accord 750 mg filmsko obložene tablete Rožnate, podolgovate, bikonveksne tablete, z vtisnjeno oznako ‘L 66' in zarezo na eni strani ter brez oznak na drugi strani.
The blisters are further packed in to carton with leaflet in pack size of 10, 20, 30, 50, 60, 100 and 200 tablets per pack. 
Pretisni omoti so pakirani v škatlice po 10, 20, 30, 50, 60, 100 in 200 tablet.
In several cases of alopecia, recovery was observed when levetiracetam was discontinued.Bone marrow suppression was identified in some of the cases of pancytopenia. 
V nekaterih primerih alopecije so po prekinitvi zdravljenja z levetiracetamom opazili izboljšanje.
Levetiracetam Accord 500 mg film-coated tablets Yellow coloured, oval, biconvex, debossed ‘L 65' and break line on one side and plain on the other side. 
Levetiracetam Accord 500 mg filmsko obložene tablete Rumene, podolgovate, bikonveksne tablete, z vtisnjeno oznako ‘L 65' in zarezo na eni strani ter brez oznak na drugi strani.
Then CLcr is adjusted for body surface area (BSA) as follows: 
72 x koncentracija kreatinina v serumu (mg/dl) CLcr je prilagojen na telesno površino (BSA -»body surface area«) na sledeč način: CLcr (ml/min)
Levetiracetam Accord 750 mg film-coated tablets Levetiracetam 
Levetiracetam Accord 750 mg filmsko obložene tablete levetiracetam
Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents including levetiracetam. 
Pri bolnikih, ki so se zdravili z antiepileptiki (vključno z levetiracetamom), so poročali o samomoru, poskusu samomora, samomorilnem razmišljanju in vedenju.
- If you notice any slow down in the growth or unexpected puberty development of your child, please contact your doctor - A small number of people being treated with anti-epileptics such as Levetiracetam Accord have had thoughts of harming or killing themselves. 
• če ste pri otroku opazili počasnejšo rast ali nepričakovan razvoj v puberteti, se posvetujte z zdravnikom.
0.20 ml/kg) once daily (3) (5) (1) Levetiracetam oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. 
(1) Pri odmerkih, manjših od 250 mg, pri odmerkih, ki niso večkratniki 250 mg in priporočenega odmerjanja zato ni mogoče doseči z več tabletami, in pri bolnikih, ki ne morejo požirati tablet, je treba uporabiti levetiracetam v obliki peroralne raztopine.
3.5 to 10.5 mg /kg (0.035 to 0.105 ml/kg) twice daily 
3,5 do 10,5 mg/kg (0,035 do 0,105 ml/kg)
Amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia,disturbance in attention 
glavobol konvulzije, motnje ravnotežja, omotica, letargija, tremor amnezija, oslabljen spomin, poslabšana koordinacija/ataksija, parestezija, motnje pozornosti horeoatetoza, diskinezija, hiperkinezija, motnje hoje, encefalopatija
Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with Levetiracetam overdoses. 
Pri prevelikem odmerjanju zdravila Levetiracetam Accord so opažali somnolenco, agitiranost, agresivnost, zmanjšano stopnjo zavesti, depresijo dihanja in komo.
PVC-Alu blister 
makrogol smukec
Levetiracetam Accord 1000 mg film-coated tablets Each film-coated tablet contains 1000 mg levetiracetam 
Levetiracetam Accord 1.000 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 1.000 mg levetiracetama.
This medicine has been prescribed for you only. 
− Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
What Levetiracetam Accord contains: 
Zdravilo Levetiracetam Accord se uporablja:
An oral solution is a formulation more appropriate to infants and children under the age of 6 years and to children and adolescent (from 6 to 17 years) weighing less than 50kg and when tablets don't allow accurate dosage. 
Za dojenčke in otroke, mlajše od 6 let, za otroke in mladostnike (od 6 do 17 let), lažjih od 50 kg in kadar s tabletami ne moremo zagotoviti natančnega odmerjanja je zdravilo Levetiracetam Accord 100 mg/ml peroralna raztopina primernejša farmacevtska oblika.
1000 mg: polyvinyl alcohol, titanium dioxide (E171), macrogol, talc 
polivinilalkohol, titanov dioksid (E171), makrogol, smukec
Levetiracetam oral solution is the preferred formulation for use in this population. 
Pri tej populaciji je najprimernejša farmacevtska oblika za uporabo zdravila levetiracetam peroralna raztopina.
Yellow coloured, oval, biconvex, film coated tablet, debossed ‘L 65' and break line on one side and plain on the other side. 
Rumene, podolgovate, bikonveksne, filmsko obložene tablete z vtisnjeno oznako ‘L 65' in zarezo na eni strani ter brez oznak na drugi strani.
Nervous system disorders 
Bolezni živčevja somnolenca,
Blood and lymphatic system disorders 
Aluminijast/PVC pretisni omot
Levetiracetam Accord 1000 mg film-coated tablets White to off white, oval, biconvex, debossed ‘L 67' and break line on one side and plain on the other side. 
Levetiracetam Accord 1.000 mg filmsko obložene tablete Bele ali umazano bele, podolgovate, bikonveksne tablete, z vtisnjeno oznako ‘L 67' in zarezo na eni strani ter brez oznak na drugi strani.
NAME OF THE MEDICINAL PRODUCT Levetiracetam Accord 500 mg film-coated tablets Levetiracetam 
Levetiracetam Accord 500 mg filmsko obložene tablete levetiracetam
Levetiracetam Accord 250 mg film-coated tablets Levetiracetam 
Levetiracetam Accord 250 mg filmsko obložene tablete levetiracetam
Pink coloured, oval, biconvex, film coated tablet, debossed ‘L 66' and break line on one side and plain on the other side. 
Rožnate, podolgovate, bikonveksne, filmsko obložene tablete z vtisnjeno oznako ‘L 66' in zarezo na eni strani ter brez oznak na drugi strani.
Mild 
MedDRA
7 to 14 mg /kg (0.07 to 0.14 ml/kg)once daily (2) 
0,14 ml/kg) enkrat na dan (2) (4)
7 to 21 mg /kg (0.07 to 0.21 ml/kg) twice daily 
7 do 21 mg/kg (0,07 do
STATEMENT OF ACTIVE SUBSTANCE (S) Each film-coated tablet contains 500 mg levetiracetam. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena filmsko obložena tableta vsebuje 500 mg levetiracetama.
Levetiracetam Accord 1000 mg film-coated tablet Levetiracetam 
Levetiracetam Accord 1.000 mg filmsko obložene tablete levetiracetam
EU/1/11/712/015-021 (10/20/30/50/60/100/200 tablets in PVC/alu Blister) EU/1/11/712/035-037 (30/60/100tablets in Unit dose Blister) 
EU/1/11/712/015-021 (10/20/30/50/60/100/200 tablet v pretisnih omotih iz PVC-ja/aluminija) EU/1/11/712/035-037 (30/60/100 tablet v enoodmernih pretisnih omotih)
Levetiracetam Accord 250 mg film-coated tablets Each film-coated tablet contains 250 mg levetiracetam 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Levetiracetam Accord 250 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 250 mg levetiracetama.
How to store Levetiracetam Accord 
Shranjevanje zdravila Levetiracetam Accord
White to off white, oval, biconvex, film coated tablet, debossed ‘L 67' and break line on one side and plain on the other side. 
Bele ali umazano bele, podolgovate, bikonveksnefilmsko obložene tablete z vtisnjeno oznako ‘L 67' in zarezo na eni strani ter brez oznak na drugi strani.
EU/1/11/712/001-007 (10/20/30/50/60/100/200 tablets in PVC/alu Blister) EU/1/11/712/029-031(30/60/100 tablets in Unit dose Blister) 
EU/1/11/712/001-007 (10/20/30/50/60/100/200 tablet v pretisnih omotih iz PVC-ja/aluminija) EU/1/11/712/029-031(30/60/100 tablet v enoodmernih pretisnih omotih)
5 to 15 mg /kg (0.05 to 0.15 ml/kg) twice daily 
5 do 15 mg/kg (0,05 do
White to off white, oval, biconvex, film coated tablet, debossed ‘L 64' and break line on one side and plain on the other side. 
Bele ali pastel bele barve, podolgovate, bikonveksne, filmsko obložene tablete, z vtisnjeno oznako ‘L 64' in zarezo na eni strani ter brez oznak na drugi strani.
EU/1/11/712/008-014 (10/20/30/50/60/100/200 tablets in PVC/alu Blister) EU/1/11/712/032-034 (30/60/100tablets in Unit dose Blister) 
EU/1/11/712/008-014 (10/20/30/50/60/100/200 tablet v pretisnih omotih iz PVC-ja/aluminija) EU/1/11/712/032-034 (30/60/100 tablet v enoodmernih pretisnih omotih)
Each film-coated tablet contains 250 mg levetiracetam. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena filmsko obložena tableta vsebuje 250 mg levetiracetama.
EU/1/11/712/022-028 (10/20/30/50/60/100/200 tablets in PVC/alu Blister) EU/1/11/712/038-040(30/60/100tablets in Unit dose Blister) 
EU/1/11/712/022-028 (10/20/30/50/60/100/200 tablet v pretisnih omotih iz PVC-ja/aluminija) EU/1/11/712/038-040 (30/60/100 tablet v enoodmernih pretisnih omotih)
7 to 14 mg /kg (0.07 to 0.14 ml/kg) twice daily 
7 do 14 mg/kg (0,07 do
MARKETING AUTHORISATION NUMBER(S) EU/1/11/712/015-021 (10/20/30/50/60/100/200 tablets in PVC/alu Blister) EU/1/11/712/035-037 (30/60/100tablets in Unit dose Blister) 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/11/712/015-021 (10/20/30/50/60/100/200 tablet v pretisnih omotih iz PVC-ja/aluminija) EU/1/11/712/035-037 (30/60/100 tablet v enoodmernih pretisnih omotih)
PVC/Alu blister pack: 
Zdravilo je na voljo v pretisnih omotih iz PVC-ja/aluminija:
MARKETING AUTHORISATION NUMBER(S) EU/1/11/712/001-007 (10/20/30/50/60/100/200 tablets in PVC/alu Blister) EU/1/11/712/029-031(30/60/100tablets in Unit dose Blister) 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/11/712/001-007 (10/20/30/50/60/100/200 tablet v pretisnih omotih iz PVC-ja/aluminija) EU/1/11/712/029-031(30/60/100 tablet v enoodmernih pretisnih omotih)
MARKETING AUTHORISATION NUMBER(S) EU/1/11/712/022-028 (10/20/30/50/60/100/200 tablets in PVC/alu Blister) EU/1/11/712/038-040 (30/60/100tablets in Unit dose Blister) 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/11/712/022-028 (10/20/30/50/60/100/200 tablet v pretisnih omotih iz PVC-ja/aluminija) EU/1/11/712/038-040 (30/60/100 tablet v enoodmernih pretisnih omotih)
MARKETING AUTHORISATION NUMBER(S) EU/1/11/712/008-014 (10/20/30/50/60/100/200 tablets in PVC/alu Blister) EU/1/11/712/032-034 (30/60/100tablets in Unit dose Blister) 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/11/712/008-014 (10/20/30/50/60/100/200 tablet v pretisnih omotih iz PVC-ja/aluminija) EU/1/11/712/032-034 (30/60/100 tablet v enoodmernih pretisnih omotih)
NAME OF THE MEDICINAL PRODUCT Levetiracetam Accord 1000 mg film-coated tablets Levetiracetam STATEMENT OF ACTIVE SUBSTANCE (S) Each film-coated tablet contains 1000 mg levetiracetam. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena filmsko obložena tableta vsebuje 1.000 mg levetiracetama.
Each film-coated tablet contains 750 mg levetiracetam. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena filmsko obložena tableta vsebuje 750 mg levetiracetama
5 to 10 mg /kg (0.05 to 0.10 ml/kg) twice daily 
5 do 10 mg/kg (0,05 do
--1 Live attenuated avian infectious bronchitis virus (IBV), variant strain 4-91: ≥3.6 log10 EID50* per dose * EID50: 50% embryo infective dose - the virus titre required to produce infection in 50% of the embryos inoculated. 
--1 Živi, oslabljeni variantni sev virusa kužnega bronhitisa perutnine (IBV) 4-91: ≥ 3,6 log 10 EID50* na odmerek * EID50: 50-odstotni infektivni odmerek za zarodke - titer virusa, ki povzroči okužbo pri 50 % inokuliranih zarodkov
3 Bottles 
3 kapalni vsebniki
1 Bottle 
1 kapalni vsebnik
If so, treatment should be stopped immediately. 
Če se to zgodi, je treba takoj prekiniti zdravljenje.
After 3 weeks a break of at least 2 weeks is required. 
Po treh tednih je potreben premor vsaj dveh tednov.
This means that there are bibliographic data providing scientific evidence of their effectiveness and safety when used in this way, covering a period of at least 10 years in the EU. 
To pomeni, da obstajajo podatki v literaturi z znanstvenimi dokazi o njihovi učinkovitosti in varnosti pri uporabi na navedene načine, ki zajemajo obdobje vsaj 10 let v EU.
In rare cases allergic skin reactions can occur. 
V redkih primerih lahko pride do alergijskih kožnih reakcij.
Capsicum should only be used in adults over the age of 18 years and should not be used continuously for more than 3 weeks. 
Plodovi paprike se smejo uporabljati samo pri odraslih, starejših od 18 let, in se ne smejo uporabljati neprekinjeno več kot tri tedne.
Overstimulating the receptors makes them become ‘desensitised' and no longer able to respond to the stimuli that normally cause pain. 
Receptorji s čezmernim spodbujanjem postanejo „desenzibilizirani“ in se ne morejo več odzivati na dražljaje, ki navadno povzročajo bolečino.
This means that it stimulates the TRPV1 receptor, which is found in the nociceptors (pain receptors) in the skin. 
To pomeni, da spodbuja receptor TRPV1, ki ga najdemo v nociceptorjih (receptorjih za bolečino) v koži.
Capsicum annuum L. var. minimum (Miller) Heiser and small fruited varieties of Capsicum frutescens L., fructus 
Capsicum annuum L. var. minimum (Miller) Heiser in različice z majhnimi plodovi Capsicum frutescens L. , fructus
This summary is not intended to provide practical advice on how to use medicines containing capsicum. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o uporabi zdravil, ki vsebujejo plod paprike.
Capsicum contains a substance known as capsaicin. 
Plod paprike vsebuje snov, imenovano kapsaicin.
The capsaicin is used to overstimulate the TRPV1 receptors. 
Kapsaicin se uporablja za čezmerno spodbujanje receptorjev TRPV1.
Capsaicin is a selective agonist of the ‘transientreceptor-potential-vanilloid-1' (TRPV1) receptor. 
Kapsaicin je selektivni agonist „vaniloidnega receptorja TRP podtipa 1“ (TRPV1).
The HMPC conclusions on the use of capsicum medicines relief of muscle pain are based on their ‘wellestablished use' in this condition. 
Zaključki odbora HMPC o uporabi zdravil za lajšanje mišične bolečine, ki vsebujejo plod paprike, temeljijo na njihovi „dobro uveljavljeni medicinski uporabi“ pri tem stanju.
Further information on the risks associated with capsicum medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Dodatne informacije o tveganjih, povezanih z zdravili, ki vsebujejo plod paprike, vključno z ustreznimi previdnostnimi ukrepi za njihovo varno uporabo, so na voljo v monografiji na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
Capsicum preparations are obtained by ethanol or propanol extraction (a technique used to extract compounds from plant parts by dissolving them in alcohol). 
Pripravki plodov paprike se pridobijo z ekstrakcijo s pomočjo etanola ali propanola (tehniko, ki se uporablja za ekstrakcijo snovi iz rastlinskih delov z raztapljanjem v alkoholu).
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of capsicum. 
To je povzetek znanstvenih zaključkov Odbora za zdravila rastlinskega izvora (HMPC) v zvezi z medicinsko uporabo plodov paprike.
The HMPC concluded that, on the basis of its well-established use, capsicum can be used for the relief of muscle pain, such as low back pain. 
Odbor HMPC je zaključil, da se lahko plod paprike na podlagi dobro uveljavljene medicinske uporabe uporablja za lajšanje mišičnih bolečin, kot so bolečine v spodnjem delu hrbta.
In its assessment, the HMPC considered a number of clinical studies which showed improvements in pain relief following treatment with capsicum medicated plaster and skin preparations compared with placebo (a dummy treatment). 
Pri svoji oceni je odbor HMPC upošteval številne klinične študije, ki so pokazale pomembno lajšanje bolečine pri zdravljenju z zdravilnimi obliži in pripravki za kožo, ki vsebujejo plod paprike, v primerjavi s placebom (zdravilom brez zdravilne učinkovine).
Capsicum is the common name for the fruits of the plant Capsicum annuum L. var. minimum (Miller) Heiser and Capsicum frutescens L. These are types of peppers that are cultivated or gathered to obtain the plant parts for medicinal use. 
Plod paprike je splošno ime za sadeže rastlin Capsicum annuum L. var. minimum (Miller) Heiser in Capsicum frutescens L. To so vrste paprike, ki se gojijo ali nabirajo za pridobivanje delov rastline za medicinsko uporabo.
How does capsicum work as a medicine? 
Kako plod paprike deluje kot zdravilo?
The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing capsicum. 
Ugotovitve odbora HMPC države članice EU upoštevajo pri ocenjevanju vlog za izdajo dovoljenja za promet z zdravili rastlinskega izvora, ki vsebujejo plod paprike.
Any applications for the licensing of medicines containing capsicum have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC. 
Vlogo za izdajo dovoljenja za promet z zdravili, ki vsebujejo plod paprike, je treba predložiti pristojnemu nacionalnemu organu za zdravila, ki bo to vlogo za izdajo dovoljenja za promet z zdravilom rastlinskega izvora ocenil in upošteval znanstvene zaključke odbora HMPC.
Further information on the HMPC assessment of capsicum medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Dodatne informacije o oceni zdravil, ki vsebujejo plod paprike, ki jo je opravil odbor HMPC, vključno z njegovimi znanstvenimi zaključki, so na voljo na spletni strani agencije pod zavihkom »Vsi dokumenti«: ema.europa.eu/Find medicine/Herbal medicines for human use.
Information on the use and licensing of capsicum medicines in EU Member States should be obtained from the relevant national authorities. 
Za informacije o uporabi in dovoljenjih za promet z zdravili, ki vsebujejo plod paprike, v državah članicah EU se obrnite na pristojni nacionalni organ.
Herbal medicines containing capsicum are usually available in a medicated plaster or in semi-solid forms to be applied to the skin (such as creams). 
Zdravila rastlinskega izvora, ki vsebujejo plod paprike, so navadno na voljo kot zdravilni obliži ali poltrdne oblike, ki se nanašajo na kožo (kot so kreme).
How are capsicum medicines approved in the EU? 
Kako so zdravila, ki vsebujejo plod paprike, odobrena v EU?
Detailed instructions on how to use capsicum medicines and who can use them can be found in the package leaflet that comes with the medicine. 
Podrobna navodila o tem, kako uporabljati zdravila, ki vsebujejo plod paprike in kdo jih sme uporabljati, so v navodilu za uporabo, ki je priloženo posameznemu zdravilu.
Capsicum 
Plod paprike
What evidence supports the use of capsicum medicines? 
Kateri dokazi podpirajo uporabo zdravil, ki vsebujejo plod paprike?
Other information about capsicum medicines 
Druge informacije o zdravilih, ki vsebujejo plod paprike
Capsicum medicines can cause reddening and a burning sensation on the areas of the skin where they are applied. 
Zdravila, ki vsebujejo plod paprike, lahko povzročajo pordelost in pekoč občutek na delih kože, kamor se nanesejo.
For more information about treatment with capsicum medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravili, ki vsebujejo plod paprike, preberite navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujte z zdravnikom ali farmacevtom.
Capsicum medicines must not be used in patients allergic to other sources of capsaicin and capsaicinlike compounds (e.g. paprika or chilli) and must not be applied onto broken skin, wounds and eczema. 
Zdravila, ki vsebujejo plod paprike, se ne smejo uporabljati pri bolnikih, alergičnih na druge vire kapsaicina in kapsaicinu podobne snovi (npr. papriko ali čili).
What are the risks associated with capsicum medicines? 
Kakšna tveganja so povezana z zdravili, ki vsebujejo plod paprike?
For practical information about using capsicum medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist. 
Za praktične informacije o njihovi uporabi naj bolniki preberejo navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujejo z zdravnikom ali farmacevtom.
What is capsicum? 
Kaj je plod paprike?
Interactions with other medical products and other forms of interaction: 
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij:
Rectal temperatures should then return to normal values. 
Nato se rektalna temperatura vrne na normalno vrednost.
Adjuvants: Aluminium hydroxide (Al3+) 
aluminijev hidroksid (Al3+)
*(Cycling value (Ct) ≥ 36 by a validated RT-PCR method, indicating no presence of viral genome) 
*(Ciklična vrednost (Ct) ≥ 36 pri validirani metodi RT-PCR, kar kaže, da virusni genom ni prisoten)
Pharmacotherapeutic group: Inactivated viral vaccines - Bluetongue virus. 
Farmakoterapevtska skupina: Inaktivirana virusna cepiva - virus bolezni modrikastega jezika.
Administer one dose of 2 ml according to the following vaccination scheme: 1st injection: from 2.5 months of age. 
Dajte en odmerek (2 ml) v skladu z naslednjim programom cepljenja: 1. injekcija: od 2,5 meseca starosti.